P2Y₁₂ inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials.

ABSTRACT:

Aim

To compare the efficacy and safety of P2Y₁₂ inhibitor or aspirin monotherapy for secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD).

Methods and results

Medline, Embase, and Cochrane Central databases were searched to identify randomized trials comparing monotherapy with a P2Y₁₂ inhibitor versus aspirin for secondary prevention in patients with ASCVD (cardiovascular, cerebrovascular, or peripheral artery disease). The primary outcome was major adverse cardiac events (MACE). Secondary outcomes were myocardial infarction (MI), stroke, all-cause mortality, and major bleeding. A random-effects model was used to calculate risk ratios (RR) and the corresponding 95% confidence interval (CI) and heterogeneity among studies

SUBMITTER: Aggarwal D 

PROVIDER: S-EPMC9242055 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature